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Abstract
Tumor accumulation and therapeutic activity of Stealth liposomes loaded with doxorubicin (DXR) were examined in
Balb/c nude mice xenografts inoculated subcutaneously with the human small cell lung cancer (SCLC) cell line, H69. Mice
were treated with non-targeted liposomes (SL) or liposomes targeted with antagonist G coupled to the liposome surface
(SLG). SLG showed 30^44-fold higher binding to H69 cells harvested from H69 xenografts than SL. At 48 and 72 h post in-
jection, tumor accumulation of [125I]tyraminylinulin-containing liposomes was shown to be dependent on liposome size but in-
dependent of the presence of the targeting ligand. Maximum tumor uptake of either SLG or SL ranged from 2 to 4% of injected
dose/g of tissue. In therapeutic studies, mice received three weekly injections of 3 or 6 mg free DXR/kg or 3 or 10 mg liposomal
DXR/kg at initial tumor volumes of either 7 or 33 mm3. The therapeutic efficacy of DXR-containing SL or SLG was signi-
ficantly improved over free DXR, but SLG did not improve anti-tumor efficacy relative to SL. Stealth liposomes containing
DXR have potential as a therapy against human SCLC tumors. ß 2001 Elsevier Science B.V. All rights reserved.
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1. Introduction
Lung cancer is still the leading cause of cancer-
related deaths in the developed world [1]. Small cell
lung cancer (SCLC) accounts for 25% of all lung
neoplasms and is characterized by early and wide-
spread metastasis with a 5 year survival rate of less
than 5% [2]. The aggressiveness of this disease is
related to its anchorage-independent proliferation
[3], and to the autocrine and paracrine growth loops
that govern SCLC [4,5]. SCLC cells secrete multiple
neuropeptides that bind speci¢c receptors on the sur-
face of those same SCLC cells, triggering a cascade
of intracellular signals that culminates in DNA syn-
thesis and cell proliferation [5]. The understanding of
these mechanisms has created new opportunities for
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Abbreviations: SCLC, small cell lung cancer; SL, sterically
stabilized liposomes; SLG, antagonist G-coupled sterically stabi-
lized liposomes; mAb, monoclonal antibody; DXR, doxorubicin;
HSPC, fully hydrogenated soy phosphatidylcholine; PEG-DSPE,
methoxypoly(ethylene glycol) (Mr 2000) distearoylphosphatidyl-
ethanolamine; CHOL, cholesterol ; PDP-PEG-DSPE, N-(3P-(pyri-
dyldithio)propionoyl)aminopoly(ethylene glycol) (Mr 2000) dis-
tearoylphosphatidylethanolamine; MAL-PEG-DSPE, male-
imide-derivatized poly(ethylene glycol) (Mr 2000) distearoylphos-
phatidylethanolamine; HEPES, N-(2-hydroxyethyl)piperazine-
NP-(2-ethanesulfonic acid); EMCS, O-maleimidocaproic acid N-
hydroxysuccinimide ester; MES, 2-(N-morpholino)ethanesulfonic
acid; PL, phospholipid; [3H]CHE, [1K,2K(n)-3H]cholesteryl hex-
adecyl ether; TI, tyraminylinulin
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therapeutic intervention, leading to the development
of broad spectrum neuropeptide antagonists, notably
the hexapeptide analogue of the neurotransmitter
substance P, [D-Arg6,D-Trp7;9,NmePhe8]-substance
P (6^11), antagonist G. Antagonist G competitively
blocks the mitogenic action of neuropeptides like
vasopressin, gastrin-releasing peptide and bradykinin
at the receptor level [6,7], and has been shown to
inhibit SCLC proliferation in vitro and in vivo
[5,6,8]. As a result, antagonist G is entering phase
II clinical trials for the treatment of SCLC [9].
Although broad spectrum neuropeptide antagonists
might be useful antiproliferative agents against
SCLC, at present chemotherapy, along with radio-
therapy, is still the major treatment modality [10].
Stealth liposomes (SL), sterically stabilized with
methoxypoly(ethylene glycol)distearoylphosphatidyl-
ethanolamine conjugates (PEG-DSPE), have long
circulation half-lives following intravenous injection,
resulting in increased tumor accumulation of associ-
ated drugs and improved therapeutic e⁄cacy relative
to standard therapy [11^13]. Although these features
led to the clinical approval of doxorubicin-containing
Stealth liposomes for the treatment of a number of
solid tumors including Kaposi’s sarcoma [14] and
ovarian cancer [15], its e⁄cacy against SCLC has
not yet been evaluated. The therapeutic e⁄cacy of
Stealth liposomal drugs has been shown to be further
improved in some model systems when ligands like
monoclonal antibodies (mAb) that selectively bind to
internalizing receptors on cancer cells are attached to
the distal ends of PEG chains grafted to the lipo-
somal surface [16,17]. This strategy has resulted in
therapeutic improvements over non-targeted formu-
lations when treatments were started at the early
stages of tumor development when cells were easily
accessible in the lung [18,19], or when cells were
within the vasculature [20] or in the peritoneal cavity
[20]. In the case of more advanced solid tumors,
some mAb-targeted liposomal drug formulations
have failed to show any therapeutic advantage over
non-targeted liposomes [19,21], while other antibody-
targeted formulations have had an advantage [22].
We have recently shown that antagonist G could
be covalently coupled to the end of PEG-grafted
Stealth liposomes (SLG). This resulted in improved
cytotoxicity of doxorubicin (DXR)-containing SLG
(DXR-SLG) against the SCLC H69 cell line relative
to non-targeted liposomes [23,24]. In this work, we
studied the biodistribution of sterically stabilized
liposomes, with or without antagonist G, in Balb/c
nude mice bearing subcutaneous xenografts of the
SCLC cell line, H69. The therapeutic activity of
DXR-containing SL, compared to SLG or free
drug, was evaluated in the treatment of SCLC pri-
mary tumors.
2. Materials and methods
2.1. Materials
Antagonist G was synthesized by Alberta Peptide
Institute (Edmonton, AB, Canada). Fully hydrogen-
ated soy phosphatidylcholine (HSPC), methoxypoly-
(ethylene glycol) (Mr 2000) distearoylphosphatidyl-
ethanolamine (PEG-DSPE) and N-(3P-(pyridyldit-
hio)propionoyl)aminopoly(ethylene glycol) (Mr 2000)
distearoylphosphatidylethanolamine (PDP-PEG-
DSPE) were generous gifts of Alza (Mountain
View, CA, USA). Maleimide-derivatized PEG2000-
DSPE (MAL-PEG-DSPE) was synthesized by
Shearwater Polymers (Huntsville, AL, USA). Choles-
terol (CHOL) was purchased from Avanti Polar
Lipids (Alabaster, AL, USA). O-Maleimidocaproic
acid N-hydroxysuccinimide ester (EMCS), 2-imi-
nothiolane and Sigmacote were purchased from Sig-
ma (St. Louis, MO, USA). Sephadex G-50 and Se-
pharose CL-4B were purchased from Pharmacia
(Uppsala, Sweden). RPMI 1640, penicillin-strepto-
mycin and fetal bovine serum were purchased from
Gibco BRL (Grand Island, NY, USA). DXR was
obtained from Faulding (Vaudreuil, PQ, Canada).
[1K,2K(n)-3H]Cholesterylhexadecyl ether, 1.48^2.22
TBq/mmol ([3H]CHE) was purchased from Mandel
Scienti¢c (Guelph, ON, Canada). Na125I and ACS
scintillation £uid were purchased from Amersham
(Oakville, ON, Canada). Iodobeads were obtained
from Pierce (Rockford, IL, USA). Tyraminylinulin
(TI) was synthesized and [125I]tyraminylinulin
([125I]TI) was prepared as previously described [25].
All other chemicals were of analytical grade purity.
2.2. Cell line
The human classical SCLC cell line NCI-H69
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(ATCC HTB-119) was purchased from the American
Type Culture Collection and cultured in RPMI 1640
supplemented with 10% (v/v) heat-inactivated fetal
bovine serum, 100 U/ml penicillin, 100 Wg/ml strep-
tomycin and maintained at 37‡C in a humidi¢ed in-
cubator containing 5% CO2. Cells were maintained
within their exponential growth phase.
2.3. Preparation of liposomes
Liposomes were composed of HSPC:CHOL:PEG-
DSPE plus either PDP-PEG-DSPE or MAL-PEG-
DSPE at a 2:1:0.08:0.02 molar ratio (total PEG lipid
was 5 mol% of phospholipid). For [125I]TI-loaded
liposomes, the aqueous space label was added during
liposome hydration at 65‡C [26]. DXR-containing
liposomes were prepared by the ammonium sulfate
gradient method using 250 mM ammonium sulfate
(pH 5.5) in the interior of the liposomes and 100 mM
sodium acetate, 70 mM NaCl bu¡er (pH 5.5) as the
exterior bu¡er [27]. The amount of encapsulated
DXR was determined from its absorbance at 492
nm following dissolution in methanol. Liposomes
were sized by extrusion through Nucleopore ¢lters
and normally measured approx. 100 nm in diameter,
as determined by dynamic light scattering.
Preparation of SLG from liposomes containing
PDP-PEG-DSPE was carried as previously described
[16]. Activation of antagonist G was performed by
reacting it with EMCS at a 1:1 molar ratio in 25 mM
N-(2-hydroxyethyl)piperazine-NP-(2-ethanesulfonic
acid) (HEPES), 25 mM 2-(N-morpholino)ethanesul-
fonic acid (MES) and 140 mM NaCl bu¡er (pH 6.5)
for 30 min at room temperature [28]. To prepare
SLG liposomes containing MAL-PEG-DSPE, thio-
lated derivatives of antagonist G were ¢rst obtained
by reacting the peptide with 2-iminothiolane at a 1:4
molar ratio in 25 mM HEPES and 140 mM NaCl
(pH 8.0) for 1 h at room temperature [29]. Lipo-
somes in HEPES bu¡er (pH 6.5) were then incubated
overnight at room temperature with the activated
peptide [30]. Activation and coupling of antagonist
G took place in an inert N2 atmosphere in silicon-
coated glassware (Sigmacote). Free maleimide groups
were quenched with an excess of 2-mercaptoethanol
for 30 min at room temperature. Unbound antago-
nist G and 2-mercaptoethanol were removed by
chromatography on a Sepharose CL-4B column,
equilibrated in 25 mM HEPES and 140 mM NaCl
(pH 7.4). The amount of antagonist G on the lipo-
somes was determined by £uorimetry at Vem = 330
nm, Vex = 288 nm.
Phospholipid (PL) concentration was determined
from either the speci¢c activity counts of a [3H]CHE
tracer or by the Bartlett colorimetric assay [31].
2.4. Cellular association
SLG were prepared by either the PDP-PEG-DSPE
method or the MAL-PEG-DSPE method. SL or
SLG were radiolabeled with [3H]CHE, 28 kBq/
Wmol PL, and incubated for 1 h at 37‡C with
1U106 H69 cells, either grown in culture or har-
vested from H69 xenografts, and the cellular associ-
ation was determined by a previously described
method [20].
2.5. Animals
Four- to 5-week-old female Balb/c nu/nu (nude)
mice were purchased from Charles Rivers Canada
(St. Constant, PQ, Canada). After arrival, they
were given a minimum acclimation period of
1 week and received autoclaved food and water.
The mice were housed in a virus antigen-free unit
in the Health Sciences Laboratory Animal Services
facility, University of Alberta. All animal protocols
were approved by the Health Sciences Animal Policy
and Welfare Committee, University of Alberta, and
were in accordance with the Guide to the Care and
Use of Experimental Animals published by the Cana-
dian Council on Animal Care.
2.6. Xenografts
The SCLC H69 xenograft was derived by implan-
tation of 107 exponentially growing H69 cells into
the £anks of female nude mice. The xenograft was
maintained as a subcutaneous tumor in the £anks of
these animals. Tumors from donor animals were
aseptically dissected and mechanically minced and
implanted subcutaneously by trochar needle as 2^3
mm3 pieces of viable tumor tissue into the £anks of
recipient animals under methoxy£urane (Metofane,
Janssen Pharmaceutica, Toronto, ON, Canada) anes-
thesia. Xenografts used in the experiments were pas-
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saged 4^11 times in normal female nude mice. His-
tological analysis con¢rmed the pathology of the
xenografts, which was checked every passage.
2.7. Orthotopic reconstitution of human SCLC in
severe combined immunode¢cient (SCID) mice
Based on previously published work [32,33], we
made several attempts at an orthotopic reconstitu-
tion (intravenous model) of human SCLC after intra-
venous injection of 5U106 SCLC H69 cells (either
grown in culture or harvested from subcutaneous
xenografts grown in nude mice) in C.B. 17 SCID
mice. Histological examination revealed that cells
did not seed either in lungs or in any other main
tissue, like liver. Although SCID mice do not pro-
duce functional B or T cells, the presence of natural
killer cells might play a critical role in the eradication
of circulating tumor cells.
2.8. Biodistribution in tumor-bearing mice
Xenografts were allowed to grow to a mean vol-
ume of approx. 43 mm3 before starting biodistribu-
tion studies. Biodistribution of both targeted and
non-targeted liposomes, encapsulating [125I]TI, was
determined as previously described [16]. Data were
expressed as the percentage of injected dose/g of tis-
sue.
2.9. Therapeutic studies
Animals were given ear tags to allow individual
identi¢cation and tumor growth was assessed twice
a week by caliper measurements for 52 days. Tumor
volumes (V) were estimated as V =Z/6UlengthU
widthUheight [34]. The results were expressed as rel-
ative tumor volume, Vt/V0 (where V0 is the tumor
volume at the start of the treatment and Vt is the
tumor volume at any given time point) and was cal-
culated for each individual tumor at every time point
(mean relative tumor volume is a mean of relative
tumor volumes, computed for each time point and
for each individual mouse within a group) [8]. Treat-
ment groups contained 5^6 mice and treatments
(given intravenously via the tail vein) were started
when tumors reached a mean volume of approx.
7 or 33 mm3 ; the ¢rst day of treatment was desig-
nated as day 0. Treatment groups for each tumor
burden consisted of three weekly doses of 3 mg
DXR/kg of body weight of either free DXR, DXR-
SL or DXR-SLG. In some experiments mice received
10 mg DXR/kg of DXR-SL or DXR-SLG and 6 mg/
kg of free DXR. The reduction in the dose of free
DXR was necessary to avoid toxicity. All experi-
ments included an additional untreated control
group of mice that received pH 7.4 HEPES bu¡er
given under the same conditions.
2.10. Statistical analysis
Student’s t-test was used to measure statistical sig-
ni¢cance between pairs of samples. Multiple compar-
isons were performed using analysis of variance (AN-
OVA). Data were considered signi¢cant at P6 0.05.
3. Results
3.1. Biodistribution studies in tumor-bearing mice
The biodistribution of [125I]TI-labeled SL or SLG
was evaluated in Balb/c nude mice at 48 and 72 h
post injection. SLG were prepared by either the
PDP-PEG-DSPE or the MAL-PEG-DSPE coupling
methods (SLGPDP and SLGMAL, respectively).
Although a thiol ether bond was formed between
the peptide and PEG in each method, in spite of
the amount of peptide being equal (1 Wg antagonist
G/Wmol PL), there were di¡erences in the ¢nal mean
diameters of the liposomes, with the SLGPDP being
larger than the SLGMAL (170 vs. 124 nm, respec-
tively). After 48 or 72 h, the spleen uptake of either
SLGPDP or SLGMAL was approx. 5^10 times higher
than that of SL (Fig. 1). No di¡erences between up-
take of SL vs. SLG occurred in other tissues, and
with the exception of liver, uptake into other tissues
was very low. After 48 h the blood levels of both SL
and SLGMAL (SLGPDP was not determined at 48 h)
were around 6.5^9% of injected dose/g of tissue and
decreased to 1.3^1.5% of injected dose/g of tissue
after 72 h (Fig. 1).
The tumor accumulation of both SL and SLGMAL
after 48 and 72 h was similar (Ps 0.05) and reached
approx. 4% injected dose/g tissue by 72 h. The accu-
mulation of SLGPDP was approx. 12-fold less
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(P6 0.001) at 72 h, which may be related to the
larger size and higher splenic accumulation of these
liposomes (Fig. 2).
3.2. Cellular association of liposomes
Since the tumor accumulation of SLGMAL was sig-
ni¢cantly less than that of SLGPDP, we looked for
di¡erences in the cellular association of these two
samples. The term ‘cellular association’ is used to
indicate a combination of binding to the cell surface
plus internalization of the liposomes. For H69 cells
grown in culture, the cellular association of SLGMAL
was the same as SLGPDP (Fig. 3A). However, due to
the poor tumor uptake of SLGPDP, only SLGMAL
were used in further experiments.
Given that receptor expression on the surface of
tumor cells is crucial for receptor targeting-based
strategies, the cellular association of SLGMAL with
H69 cells harvested from 4th and 11th generation
subcutaneous xenografts was tested. Cellular associ-
ation of SLGMAL with H69 cells harvested from a
11th generation tumor was slightly lower than that
from a 4th generation tumor, but was still approx.
40-fold higher than the cellular association seen for
SL, indicating that receptors for antagonist G were
still being expressed at levels su⁄cient for targeting
(Fig. 3B).
3.3. Therapeutic studies
Balb/c nu/nu mice bearing subcutaneous H69 cell
xenografts were treated with free DXR, non-targeted
liposomal DXR (DXR-SL) or antagonist G-targeted
liposomal DXR (DXR-SLG). No DXR dose re-
sulted in more than 20% weight loss and no treat-
ment-related deaths were observed. In these mice, the
maximum tolerated dose for free DXR was 6 mg/kg,
Fig. 2. Tumor accumulation of liposomes in Balb/c nu/nu mice
xenografted subcutaneously with H69 cells. Conditions and
symbols are as in Fig. 1. After 48 or 72 h, tumors were col-
lected and counted for 125I label. Results were expressed as the
percentage of injected dose/g tissue. Each point represents the
average of three mice ( þ S.D.).
Fig. 1. Tissue distributions of liposomes in Balb/c nu/nu mice
xenografted subcutaneously with H69 cells. [125I]TI-labeled non-
targeted (open bar) or antagonist G-targeted liposomes pre-
pared by either the PDP-PEG-DSPE method (black bar) or the
MAL-PEG-DSPE method (cross-hatched bar) were injected via
the tail vein as a single bolus dose (0.5 Wmol PL/mouse). After
(A) 48 h or (B) 72 h, major organs and blood were collected
and counted for 125I label. Results were expressed as the per-
centage of injected dose/g tissue. Each point represents the aver-
age of three mice ( þ S.D.).
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although doses of 10 mg DXR/kg of the liposomal
drug were well tolerated. Mean relative tumor vol-
umes for the various treatments were determined
(Figs. 4 and 5).
Treatment of tumor-bearing mice with DXR-SL
or DXR-SLG at low DXR doses (3 mg DXR/kg)
when the tumor was at the beginning of its exponen-
tial growth phase (mean tumor volume of approx.
7 mm3), caused a slight decrease in the tumor growth
rate relative to non-treated tumors or free DXR, but
no di¡erences between the targeted and the non-tar-
geted liposomes were observed (Fig. 4A). Treatment
of mice with DXR-SL or DXR-SLG at 10 mg DXR/
kg, at a tumor volume of 7 mm3, almost completely
inhibited tumor growth, although no di¡erences were
observed between the two liposomal treatments. Free
DXR, at its maximum tolerated dose of 6 mg/kg,
was signi¢cantly less e¡ective than SL or SLG (Fig.
4B).
Fig. 4. Antitumor e⁄cacy of various formulations of DXR
against early SCLC H69 tumor xenografts grown in Balb/c nu/
nu mice. Treatments started when the mean tumor volume
reached approx. 7 mm3 and the ¢rst day of treatment was des-
ignated as day 0. Mice were treated on days 0, 7 and 14 with:
(A) 3 mg DXR/kg of body weight of either free DXR (8),
DXR-SL (a) or DXR-SLG (b) ; (B) 6 mg DXR/kg of body
weight of free DXR (8), and 10 mg DXR/kg of body weight
of either DXR-SL (a) or DXR-SLG (b). Untreated controls
received pH 7.4 HEPES bu¡er (R). Arrows indicate the time
points of treatment. The results were expressed as mean relative
tumor volume. Each point represents the average of 5^6 mice
þ S.E.M.
Fig. 3. Cellular association of [3H]CHE-labeled liposomes with
H69 cells. Liposomes composed of HSPC:CHOL:PEG-
DSPE:PDP-PEG-DSPE or MAL-PEG-DSPE at a 2:1:0.08:
0.02 molar ratio (0.1^0.8 mM PL/well), were incubated with
1U106 H69 cells. (A) SCLC H69 cells grown in culture
were incubated at 37‡C for 1 h with either SLGPDP (R) or
SLGMAL (b). (B) SCLC H69 cells harvested from H69 xeno-
grafts obtained after four passages or 11 passages were incu-
bated with SL (999a999 and - - -a- - -, for tumors with
four and 11 passages, respectively) or SLGMAL (999b999
and - - -b- - -, for tumors with four and 11 passages, respec-
tively). The amount of [3H]CHE-liposomes associated with cells
was determined from the initial speci¢c activity of [3H]CHE-
liposomes. Data were expressed as nmol of PL/106 cells. Each
point is the mean of three samples, þ S.D.
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For treatments at 3 mg DXR/kg with higher tu-
mor burdens (mean volume of approx. 33 mm3, Fig.
5A), free DXR did not have any therapeutic activity.
Treatment with either DXR-SLG or DXR-SL caused
some inhibition of tumor growth, but no di¡erences
were observed between the two liposomal groups.
Treatment with 10 mg/kg DXR-SLG or DXR-SL
resulted in signi¢cant tumor growth inhibition (Fig.
5B). Treatment with free DXR at its maximum tol-
erated dose of 6 mg/kg was less e¡ective than either
liposomal formulation, but more e¡ective than un-
treated control (Fig. 5B).
4. Discussion
The aggressiveness of SCLC, along with the low
survival rate of patients with this type of tumor,
demands the development of novel and more e⁄cient
therapeutic strategies. The unique pathophysiological
features exhibited by most solid tumors, such as an-
giogenesis, leaky blood vessels and impaired lym-
phatic drainage provide an opportunity for the selec-
tive accumulation of liposomes. The long circulating
half-lives of drugs like DXR entrapped in PEG-
grafted liposomes, their in vivo stability in plasma
and their improved vascular permeability are neces-
sary for the high tumor accumulation [35] and im-
proved therapeutic e⁄cacy seen for these formula-
tions [11].
Some evidence exists for further improvements in
therapeutic e¡ects when targeting ligands, like anti-
bodies, were attached to the PEG-liposomes [20].
However, whole antibodies are probably not the
best targeting molecules. Use of whole antibodies
attached to the PEG terminus of Stealth liposomes
enhanced mononuclear phagocyte system uptake of
the liposomes via an Fc receptor-mediated mecha-
nism [36] relative to either non-targeted liposomes
or to liposomes targeted via FabP fragments that
lack the Fc region of the antibody [37]. This resulted
in a decrease of the blood residence time of the tar-
geted liposomes, which would likely reduce tumor
uptake [37,38]. Even if the targeted liposomes are
distributed to solid tumors, their penetration into
the tumor interior might be compromised by their
binding to cell surface receptors at the tumor periph-
ery [39]. Tumor penetration may be improved
through the use of small ligands with reduced avidity
for their target (relatively to whole antibodies), like
antibody FabP fragments or single chain antibody
fragments, or peptides [40].
Previous work in our laboratory has demonstrated
improved cytotoxicity against the human SCLC H69
cell line of DXR-containing antagonist G-targeted
liposomes, relative to non-targeted liposomes
[23,24]. These results prompted us to evaluate the
tumor accumulation and the therapeutic e⁄cacy of
these formulations against H69 xenografts in Balb/c
nude mice. Small peptides have the advantage (over
antibodies) of being non-immunogenic, chemically
Fig. 5. Antitumor e⁄cacy of various formulations of DXR
against advanced SCLC H69 tumor xenografts grown in Balb/c
nu/nu mice. Treatments started when the mean tumor volume
reached approx. 33 mm3 and the ¢rst day of treatment was des-
ignated as day 0. Mice were treated on days 0, 7 and 14 with:
(A) 3 mg DXR/kg of body weight of either free DXR (8),
DXR-SL (a) or DXR-SLG (b) ; (B) 6 mg DXR/kg of body
weight of free DXR (8), and 10 mg DXR/kg of body weight
of either DXR-SL (a) or DXR-SLG (b). Untreated controls
received pH 7.4 HEPES bu¡er (R). Arrows indicate the time
points of treatment. The results were expressed as mean relative
tumor volume. Each point represents the average of 5^6 mice
þ S.E.M.
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de¢ned and able to be manufactured in large quanti-
ties without biological contaminants.
Two di¡erent coupling methods were used to pre-
pare the antagonist G-targeted liposomes in these
experiments. Liposomes made by the PDP-PEG-
DSPE method had a larger size, a greater splenic
uptake, and a reduced tumor uptake relative to lipo-
somes made by the MAL-PEG-DSPE method. The
reduced tumor uptake of SLGPDP is likely related to
both their more rapid clearance into the spleen (re-
sulting in fewer liposomes available to be distributed
to tumors) and to their larger size. Previous studies
have shown that the extravasation of PEG-grafted
liposomes from the vascular compartment into the
tumor interstitium was size-dependent, and also de-
pendent on the type of tumor, and mainly limited by
their ability to di¡use through the 100^1200 nm
pores in the vessel wall [42,43].
Although there is a substantial increase in the cel-
lular association of SLG with H69 cells harvested
from H69 xenografts (Fig. 3B), no improvement in
tumor accumulation was observed for SLG over SL
(Fig. 2). This con¢rms observations by other authors
that targeting of liposomes does not lead to increased
accumulation of the liposomes in solid tumors
[37,44,45]. It would appear that the accumulation
of targeted liposomes in solid tumors is governed
by the same processes that govern the tumor accu-
mulation of non-targeted liposomes, i.e. passive dif-
fusion and extravasation, and that peptide-targeted
liposomes may also su¡er from the ‘binding site bar-
rier’, like antibody-targeted liposomes.
Recently, FabP fragments of a fully humanized
version of the murine mAb 4D5, directed against
the glycoprotein p185HER2, were used to target
PEG-grafted liposomal DXR towards HER2-overex-
pressing human breast cancer cells (BT-474 tumor
xenografts) [41,44]. Even though the total uptake of
the liposomes into tumor was similar for the targeted
and the non-targeted liposomes in this model, tumor
regression was observed [22]. The occurrence of in-
creased tumor regression for the targeted liposomes
relative to the non-targeted liposomes could be ex-
plained by di¡erences in the intratumoral localiza-
tion between non-targeted and targeted liposomes.
Liposomes prepared with FabP fragments of mAb
4D5 were widely distributed in the intercellular
spaces throughout HER2-positive tumor tissue as
well as within the cytoplasm and in the perinuclear
spaces of HER2-positive cancer cells. Non-targeted
liposomes were mainly found in tumor-resident mac-
rophages and in perivascular areas [44].
In the therapeutic experiments with the HER2
model, even though no increase in tumor accumula-
tion was observed between targeted and non-targeted
liposomes, similar to our observations in the SCLC
model, the targeted liposomes resulted in an in-
creased therapeutic e¡ect relative to the non-targeted
liposomes [22]. In our experimental model, while the
liposomal formulations were superior to treatment
with free drug, no di¡erences in therapeutic e¡ect
were observed between DXR-SL and DXR-SLG. A
similar result was obtained when DXR-containing
liposomes were targeted with the N12A5 mAb to-
wards the HER2 antigen in a gastric cancer model,
possibly due to an absence of liposome internaliza-
tion [45]. However, as previously demonstrated, SLG
are internalized by H69 cells [23,24], so lack of inter-
nalization cannot explain the data.
One explanation might be poor vascularization of
the H69 xenograft relative to the BT-474 xenografts,
which were well vascularized [44]. Histological ex-
amination of the SCLC tumors revealed that they
are poorly vascularized, thus con¢rming macroscopic
observation. This seems to be a common feature of
SCLC xenografts [48]. This would certainly limit the
amount of liposomal drug that could accumulate in
tumors (which was 2-fold lower for the SCLC tu-
mors than for the BT-474 tumors), but one could
argue that it would a¡ect the accumulation of non-
targeted and targeted liposomes to a similar degree.
As shown in Fig. 2, there was no di¡erence in total
tumor uptake for the non-targeted versus the tar-
geted (MAL-PEG-DSPE) liposomes, so the similar
therapeutic activity for the two formulations is not
surprising. Another explanation could be related to
the presence of lower receptor densities on the H69
cells, relative to the BT-474 cells, or to down-regu-
lation of the receptors on the H69 cell in vivo, rela-
tive to that seen in vitro. The cellular association
experiments for SLG carried out with H69 cells har-
vested from H69 subcutaneous xenograft demon-
strated that the in vivo propagation of the tumor
over several generations did not compromise recep-
tor expression for antagonist G.
Antagonist G is a chemical analogue of the neuro-
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transmitter substance P with the structure ‘H-Arg-D-
Trp-NmePhe-D-Trp-Leu-Met-NH2’. The biological
action of this peptide depends on its ability to bind
receptors (namely, vasopressin receptor) on the sur-
face of H69 cells, via the amino acid sequence D-
Trp-NmePhe-D-Trp-Leu [6]. The in vivo metabolism
of antagonist G has been fully characterized [46]. It
has been shown that antagonist G is metabolized
mainly by deamidation (Met-NH2) followed by car-
boxypeptidase removal of methionine. Therefore,
under these conditions the hydrophobic core of the
peptide, which is important for its binding to tumor
cells, is left intact [46]. Moreover, in vitro studies
have shown that the metabolites retain peptide
growth factor antagonist activity against vasopressin
of the same order of magnitude as antagonist G [47].
These data strongly suggest that antagonist G is able
to maintain its receptor binding properties in vivo
and lead us to hypothesize that other factors must
contribute to the similarities in the therapeutic activ-
ity of DXR-SL and DXR-SLG.
Our results emphasize that, even when ligands
against internalizing epitopes are used for targeting,
vascular density and/or degree of perfusion within a
solid tumor can be major factors governing the ther-
apeutic success of targeted liposomal drugs. Our pre-
vious successes in treating metastatic cells in blood,
or cells that had only recently formed metastatic le-
sions in tissues [18^20], suggest that we should try
the antagonist G-targeted liposomes to eliminate mi-
grating cells in a metastatic or pseudometastatic
model. Since SCLC has the highest metastatic poten-
tial of any of the solid tumors in humans [3], antag-
onist G-targeted liposomal DXR could be useful as
an adjuvant therapy against SCLC metastatic cells
migrating in blood; however, an appropriate model
to test this hypothesis needs to be developed. Never-
theless, the results presented here point out that
DXR-containing Stealth liposomes may have poten-
tial for the treatment of human SCLC tumors.
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